new semaglutide injection Wegovy 1mg high blood pressure Ozempic: New drugs against obesity

The study included 42 patients with bilateral knee osteoarthritis who were randomly assigned to receive 3 sessions of either f-ESWT or r-ESWT at 1-week intervals

Diab Obes

Food and Drug Administration is announcing its intent to take decisive steps to restrict GLP-1 active pharmaceutical ingredients (APIs) intended for use in non-FDA-approved compounded drugs that are being mass-marketed by companies, including Hims & Hers and other compounding pharmacies, as similar alternatives to FDA-approved drugs. The agency said the actions are intended to safeguard consumers from drugs for which the FDA cannot verify quality, safety, or efficacy. The agency also emphasized ongoing concerns around promotional claims and direct-to-consumer messaging, building on the The FDA is also taking steps to combat misleading direct-to-consumer advertising and marketing following warning letters that were sent in the fall of 2025, the agency said

Understanding these behavioral patterns helps clinicians reinforce realistic expectations

If you have cardiovascular disease or significant risk, consult your clinician before beginning long-term use because of the unresolved TMAO issue